Start Date
March 31, 2011
Primary Completion Date
May 31, 2013
Study Completion Date
June 30, 2013
Eflornithine plus Sulindac
Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
Eflornithine plus Placebo
Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
Sulindac plus Placebo
Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
Lead Sponsor
Cancer Prevention Pharmaceuticals, Inc.
INDUSTRY